References

Allen JG, Bloxham DP (1989) The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 40:1-27

Brecher AR, Orlow SJ (2003) Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 49:171-182 Callen JP (1990) Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 8:355-365

Coburn PR, Shuster S (1982) Dapsone and discoid lupus erythematosus. Br J Dermatol 106:105-106

Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129:507-513 Craven NM, Griffiths CE (1996) Topical retinoids and cutaneous biology. Clin Exp Dermatol 21:1-10

Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis

Clin North Am 21:99-115 Duken CM (1984) Retinoids: a review. J Am Acad Dermatol 11:541-552

Ellis CN, Krach KJ (2001) Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45:S150-157

Furner BB (1990a) Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 29:542-547

Furner BB (1990b) Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Der-matol 29:587-590

Grupper C, Berretti B (1984) Lupus erythematosus and etretinate. In: Cunliffe WJ, Miller AJ

(eds) Retinoid therapy. MTP, Lancaster, pp 73-82 Hall RP, Lawley TJ, Smith HR, Katz SI (1982) Bullous eruption of systemic lupus erythematosus.

Ann Intern Med 97:165-170 Katz SI (1999) Sulfones. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine, 5th ed. McGraw-Hill, New York, pp 2790-2794

Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. J Am

Acad Dermatol 41:S7-S12 Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus - a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033-1041 Lang PG Jr (1979) Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1:479-492

Lindskov R, Reymann F (1986) Dapsone in the treatment of cutaneous lupus erythematosus.

Dermatologica 172:214-217 Lo JS, Berg RE, Tomecki KJ (1989) Treatment of discoid lupus erythematosus. Int J Dermatol 28:497-507

Lubach D, Wagner G (1984) Erfolgreiche Behandlung eines subakut kutanen Lupus erythematodes mit Etretinat. Aktuel Dermatol 10:142-144 Lucek RW, Colburn WA (1989) Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 10:38-62

McCormack LS, Elgart ML, Turner ML (1984) Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 11:397-401 Miyachi Y, Niwa Y (1982) Effects of KI, colchicine and dapsone on the generation of PMNL-

derived oxygen intermediates. Br J Dermatol 107:209-214 Mok CC, Lau CS (1996) Dapsone syndrome in cutaneous lupus erythematosus. J Rheumatol 23:766-768

Mok CC, Lau CS, Wong RW (1998) Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases. J Rheumatol 25:1246-1247

Newton RC, Jorizzo JL, Solomon AR Jr, Sanchez RL, Daniels JC, Bell JD, Cavallo T (1986) Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythe-matosus. Arch Dermatol 122:170-176 Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34:459-503 Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53:358-388 Peck GL, DiGiovanna JJ (1999) Retinoids. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine. 5th ed. McGraw-Hill, New York, pp 2810-2821 Pfeiffer C, Wozel G (2003) Dapsone and sulfones in dermatology: overview and update. J Am

Acad Dermatol 48:308-309 Ruzicka T, Goerz G (1981) Dapsone in the treatment of lupus erythematosus. Br J Dermatol 104:53-56

Ruzicka T,Wasserman SI, Soter NA, Printz MP (1983) Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone. J Allergy Clin Immunol 72:365-370 Ruzicka T, Meurer M, Braun-Falco O (1985) Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 65:324-329 Ruzicka T, Meurer M, Bieber T (1988) Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 124:897-902 Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127:513-518 Shornick JK, Formica N, Parke AL (1991) Isotretinoin for refractory lupus erythematosus. J Am

Acad Dermatol 24:49-52 Wiegand UW, Chou RC (1998) Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 39:S8-12

Wiegand UW, Chou RC (1998) Pharmacokinetics of acitretin and etretinate. J Am Acad Derma-tol 39:S25-33

Windhorst DB (1982) The use of isotretinoin in disorders of keratinisation. J Am Acad Derma-tol 6:708-709

Wozel G, Barth J (1988) Current aspects of modes of action of dapsone. Int J Dermatol

27:547-552

Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420-434

Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11:299-315

100 Hair Growth Tips

100 Hair Growth Tips

100 Hair Growth Tips EVERY Balding Person Should Know. This Report

Get My Free Ebook


Post a comment